遗传性I型抗凝血酶缺陷女性妊娠相关静脉血栓栓塞及产科并发症风险:回顾性单中心队列研究
该单中心回顾性队列研究纳入1980年至2018年转诊的I型抗凝血酶缺陷且有妊娠史的女性,评估妊娠相关静脉血栓栓塞(VTE)及产科并发症风险。
核心结论
- I型抗凝血酶缺陷女性妊娠期首次或复发性VTE风险高,有VTE家族史者风险最高,但无家族史者风险仍相关,提示应考虑LMWH预防。
研究设计与样本
- 单中心、回顾性队列研究,纳入1980年1月1日至2018年1月1日意大利米兰血友病与血栓中心转诊的I型抗凝血酶缺陷且有至少一次妊娠的女性,排除II型缺陷者。
临床怎么用
- 对I型抗凝血酶缺陷妊娠女性应评估VTE风险,包括VTE家族史,并考虑LMWH预防。
- LMWH使用与晚期产科并发症风险升高相关,需个体化权衡并加强监测。
局限性
- 回顾性单中心设计,样本量有限,LMWH为非随机使用,可能存在适应证混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inherited quantitative (type I) deficiency of plasma antithrombin is associated with a high risk of venous thromboembolism, which further increases in pregnancy. Inherited thrombophilia also increases the risk of obstetrical complications, but data on maternal and fetal outcomes in women with antithrombin deficiency are scarce. The aim of this study was to evaluate the risk of pregnancy-associated venous thromboembolism and obstetrical complications in women with type I antithrombin deficiency. METHODS: In this single-centre, retrospective cohort study, women who had been referred to our Hemophilia and Thrombosis Centre, Milan, Italy for a thrombophilia work-up from Jan 1, 1980, to Jan 1, 2018, with type I antithrombin deficiency and who had had at least one pregnancy were included. Women with type II anthithrombin deficiency were excluded from the study. Data on pregnancy-associated venous thromboembolism, pregnancy outcomes, and the use of low-molecular-weight heparin (LMWH) were collected to evaluate the risk of pregnancy-associated venous thromboembolism and obstetrical complications with or without use of LMWH. FINDINGS: 126 women had been referred to the hospital, of whom 88 (70%) had had at least one pregnancy. Eight were excluded because of referral for venous thromboembolism during pregnancy or the puerperium, resulting in 80 (63%)women evaluated for the risk of venous thromboembolism. One woman was excluded because of referral for obstetrical complications, resulting in 87 (69%) evaluated for risk of obstetrical complications. We observed three events of venous thromboembolism in 43 pregnancies in women treated with LMWH (7·0%, 95% CI 1·8-17·8), and 17 events in 146 pregnancies in women who did not receive LMWH (11·6%, 7·2-17·6; relative risk [RR] 0·6, 95% CI 0·2-1·9; p=0·57). The risk of venous thromboembolism without LMWH was 5·4% (95% CI 0·9-16·7) in women with a negative family history of venous thromboembolism, and 11·8% (6·4-19·6) in those with a positive family history of venous thromboembolism. Of the 87 women evaluated for the risk of obstetrical complications, miscarriages occurred in 6 (13%) of 45 pregnant women treated with LMWH and 32 (20%) of 161 women who did not receive LMWH (terminations excluded). Late obstetrical complications occurred in 11 (24%) of women treated with LMWH and nine (6%) in those who did not receive LMWH (RR 4·4, 95% CI 1·9-9·9; p=0·0006). INTERPRETATION: Our results confirm that women with type I antithrombin deficiency have a high risk of first or recurrent venous thromboembolism during pregnancy. The risk of venous thromboembolism is highest in women with a positive family history of the condition, but still relevant in those with a negative family history, suggesting that LMWH prophylaxis should also be considered in these patients. FUNDING: None.
引用
- Abbattista M, Gianniello F, Novembrino C, et al. Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study. Lancet Haematol. 2020. PMID: 32112716. doi:10.1016/S2352-3026(20)30007-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。